Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta—a hallmark of Alzheimer's disease. The findings ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Doug Whitney was supposed to develop Alzheimer's by 50. Now scientists are trying to understand why his brain remains healthy ...

Scientists believe they have found a major link between Alzheimer's disease and a dieting hack, which is followed by millions ...

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

A new biomarker test identifies very early stages of tau tangle formation, up to a decade before any tau clumps can show up ...

A groundbreaking study reveals how a rare combination of genetics, proteomics, and environmental factors may hold the key to ...